Skip to main content
SpringerLink
Log in

Triple Negative Breast Cancer

  • Review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Breast cancer is increasingly recognized a disease very heterogenous in its biological and clinical behaviour. Triple negative breast cancer lacks the expression of estrogen-, progesterone receptors and Her2/neu protein and is characterized by its unique clinical and prognostic features. This review describes the biology, pathology, prognosis, current treatment options and future directions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast cancer. Clin Cancer Res, 10: 5367–5374, 2004

    Article  PubMed  CAS  Google Scholar 

  • Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature, 406: 747–752, 2000

    Article  PubMed  CAS  Google Scholar 

  • Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS, 98: 10869–10874, 2001

    Article  PubMed  CAS  Google Scholar 

  • Rakha EA, Reis-Filho JS, Ellis IO, et al. Basal-like breast cancer: A critical review. J Clin Oncol, 26: 2568–2581, 2008

    Article  PubMed  Google Scholar 

  • Sarrio D, Rodriguez-Pinella SM, Hardisson D, et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res, 68: 989–997, 2008

    Article  PubMed  CAS  Google Scholar 

  • Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133: 704–715, 2008

    Article  PubMed  CAS  Google Scholar 

  • Honeth G, Bendahl PO, Ringner M, et al. The CD44+/CD24– phenotype is enriched in basal-like breast tumors. Breast Cancer Res, 10: R53, 2008

    Article  PubMed  Google Scholar 

  • Abraham BK, Fritz P, McClellan M, et al. Prevalence of CD44+/CD24–/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res, 11: 1154–1159, 2005

    PubMed  CAS  Google Scholar 

  • Shackleton M, Vaillant F, Simpson KJ, et al. Generation of a functional mammary gland from a single stem cell. Nature, 439: 84, 2006

    Article  PubMed  CAS  Google Scholar 

  • Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet, 40: 499, 2008

    Article  PubMed  CAS  Google Scholar 

  • Troester M, Herschkowitz J, Oh D, et al. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer, 6: 276, 2006

    Article  PubMed  Google Scholar 

  • Foulkes W, Stefansson I, Chappuis P, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst, 95: 1482–1485, 2003

    Article  PubMed  CAS  Google Scholar 

  • Rakha E, El-Sayed M, Green A, et al. Prognostic markers in triple negative breast cancer. Cancer, 109: 25–32, 2007

    Article  PubMed  CAS  Google Scholar 

  • Calza S, Hall P, Auer Ge, et al. Intrinsic molecular signature of breast cancer in a population based cohort of 412 patients. Breast Cancer Res, 8: R34, 2006

    Article  PubMed  Google Scholar 

  • Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. NEJM, 355: 560–569, 2006

    Article  PubMed  CAS  Google Scholar 

  • Rouzier R, Perou CM, Symmans WF, et al. Breast cancer subtypes respond differently to preoperative chemotherapy. Clin Cancer Res, 11: 5678–5685, 2005

    Article  PubMed  CAS  Google Scholar 

  • Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics, 7: 96, 2006

    Article  PubMed  Google Scholar 

  • Parker JS, Mullins M, Cheang MCU, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160–1167, 2009

    Article  PubMed  Google Scholar 

  • Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: Interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol, 53: 125–130, 2000

    Article  PubMed  CAS  Google Scholar 

  • Bertucci F, Finetti P, Cervera N, et al. How basal are triple negative breast cancers? Int J Cancer, 123: 236–240, 2008

    Article  PubMed  CAS  Google Scholar 

  • Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphologic features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology, 49: 22–34, 2006

    Article  PubMed  CAS  Google Scholar 

  • Glass AG, Lacey JV Jr, Carreon JD, et al. Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst, 99: 1152–1161, 2007

    Article  PubMed  Google Scholar 

  • Millikan CR, Newman B, Tse C, et al. Epidemiology of basal-like cancer. Breast Cancer Res Treat, 109(1): 123–139, 2008

    Article  PubMed  Google Scholar 

  • Carey L, Perou C, Livasy C, et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA, 265: 2492–2502, 2006

    Article  Google Scholar 

  • Maiti B, Kundrana MN, Jin T, et al. The association of metabolic syndrome with triple negative breast cancer. J Clin Oncol, 27: (abstr. 1038), 2009

    Google Scholar 

  • Dent R, Trudeau M, Pritchard KI, et al. Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 13(15 Pt 1): 4429–4434, 2007

    Article  PubMed  Google Scholar 

  • Haffty BG, Yang O, Reiss M, et al. Locoregional relapse and distant metastases in conservatively managed triple negative early-stage breast cancer. J Clin Oncol, 24: 5652–5657, 2006

    Article  PubMed  Google Scholar 

  • Cheang MCU, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple negative phenotype. Clin Cancer Res, 14: 1368–1376, 2008

    Article  PubMed  CAS  Google Scholar 

  • Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol, 59: 729–735, 2006

    Article  PubMed  CAS  Google Scholar 

  • Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential sites of relapse. Cancer Res, 68: 3108–3114, 2008

    Article  PubMed  CAS  Google Scholar 

  • Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathological features and sites of recurrence according to breast cancer subtype in the NCCN. J Clin Oncol, 27: (abstr. 543), 2009

    Google Scholar 

  • Heitz F, Harter P, Traut A, et al. Cerebral metastases in breast cancer with focus on triple negative tumors. J Clin Oncol, 26: (abstr. 1010), 2008

    Google Scholar 

  • Hayes DF, Thor AD, Dressler LG, et al. Her2 and response to paclitaxel in node positive breast cancer. NEJM, 357: 1496–1506, 2007

    Article  PubMed  CAS  Google Scholar 

  • Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9471/Cancer and Leukemia Group B Trial 9741. J Clin Oncol, 21: 1431–1439, 2003

    Article  PubMed  CAS  Google Scholar 

  • Jacquemier J, Penault-Llorca F, Mnif H, et al. Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 marker studied on tissue-microarrays. J Clin Oncol, 24: (abstr 509), 2006

  • Hugh J, Hanson J, Cheang MCU, et al. Breast Cancer Subtypes and response to docetaxel in node positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol, 27: 1168–1176, 2009

    Article  PubMed  CAS  Google Scholar 

  • Huober J, von Minckwitz G, Denkert C, et al. Neoadjuvant chemotherapy in operable breast cancer with docetaxel, doxorubicin und cyclophosphamide (TAC) or TAC followed by vinorelbine and capecitabine (NX): final results and analysis of markers predicting response to treatment. J Clin Oncol, 27: (abstr. 524), 2009

    Google Scholar 

  • Di Leo A, Isola J, Piette F, et al. A meta-analysis of phase III trials evaluating the predictive value of Her2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline based chemotherapy. Cancer Res, 2009; 69: (abstr. 705)

    Google Scholar 

  • Cheang M, Chia SK, Tu D, et al. Anthracyclins in basal breast cancer: the NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol, 2009; 27: 519

    Google Scholar 

  • Gronwald J, Byrski T, Huzarski T, et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol, 27: (abstr. 502), 2009

    Google Scholar 

  • Frasci G, Comella P, Rinaldo M, et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple negative large operable breast cancer. Ann Oncol, 20: 1185–1192, 2009

    Article  PubMed  CAS  Google Scholar 

  • Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple negative breast cancer. Ann Oncol, 19: 1847–1852, 2008

    Article  PubMed  CAS  Google Scholar 

  • Le Tourneau C, Dettwiler S, Laurence V, et al. 47% PCR rate to anthracyclines-based associated with high cyclophosphamide doses neoadjuvant chemotherapy in basal-like and triple negative breast cancer patients. Breast Cancer Res Treat, 106: (abstr. 4010), 2007

    Google Scholar 

  • Gluz O, Nitz UA, Harbeck N, et al. Triple negative breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM 01 Trial. Ann Oncol, 19: 861–870, 2008

    Article  PubMed  CAS  Google Scholar 

  • Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long term survival in patients with triple negative breast cancer. J Clin Oncol, 26: 1275–1281, 2008

    Article  PubMed  Google Scholar 

  • Tutt A, Robson M, Garber JE, et al. Phase II Trial of the oral PARP inhibitor olaparid in BRCA-deficient advanced breast cancer. J Clin Oncol, 27: (abstr. 501), 2009

    Google Scholar 

  • O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a PARP inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol, 27: (abstr. 3), 2009

  • Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434: 917, 2005

    Article  PubMed  CAS  Google Scholar 

  • Finn RS, Lau A, Kalous O, et al. Pre-clinical activity of the PARP inhibitor AZD2281 in human breast cancer cell lines and in combination with DNA damaging agents. Cancer Res, 69: (abstr. 1038), 2009

    Google Scholar 

  • Carey L, Mayer E, Marcom P, et al. TBCRC 001: EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast cancer (abstr. 307). Breast Cancer Res Treat, 106 (suppl 1): S32, 2007

    Google Scholar 

  • Corkery B, Crown J, Clynes M, et al. Epidermal growth factor receptor as a potential therapeutic target in triple negative breast cancer. Ann Oncol, 20: 862–867, 2009

    Article  PubMed  CAS  Google Scholar 

  • Linderholm BK, Klintman M, Grabau D, et al. Significantly higher expression of VEGF and shorter survival after recurrences in premenopausal node negative patients with triple negative breast cancer. Cancer Res, 69: (abstr. 1077), 2009

    Google Scholar 

  • Ryden L, Ferno M, Stal O, et al. VEGF receptor 2 is a significant negative prognostic biomarker in triple negative breast cancer: results from a controlled randomised trial of premenopausal breast cancer. Cancer Res, 69: (abstr. 1087), 2009

    Google Scholar 

  • Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. NEJM, 357: 2666–2676, 2007

    Article  PubMed  CAS  Google Scholar 

  • Finn RS, Bengala C, Ibrahim N, et al. Phase II trial of dasatinib in triple negative breast cancer: results of study CA 180059. Cancer Res, 69: (abstr. 3118), 2009

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory of Immunological and Molecular Cancer Research (LIMCR), Private Medical University Hospital Salzburg, Salzburg, Austria

    S. Ressler, B. Mlineritsch & R. Greil

Authors
  1. S. Ressler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Mlineritsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Greil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Ressler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ressler, S., Mlineritsch, B. & Greil, R. Triple Negative Breast Cancer. memo 3, 185–189 (2010). https://doi.org/10.1007/s12254-010-0232-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-010-0232-5

Keywords

Search

Navigation